The Business Of Biotech Podcast
-
Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer
2/12/2026
On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases.
-
Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie
2/6/2026
On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies.
-
BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
1/29/2026
On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, following his departure from LEO Pharma.
-
BoB@JPM: Ron Cooper, enGene
1/21/2026
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders.
-
BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics
1/15/2026
The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials.
-
A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith
1/8/2026
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK.
-
Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead
12/30/2025
This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026.
-
Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos
12/22/2025
On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai's allogeneic neuron replacement cell therapy for Parkinson's disease.
-
Modernizing Clinical Trial Operations With Merck's Jennifer Sheller
12/18/2025
On this episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for conducting trials in over 60 countries.
-
Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.
12/12/2025
On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path.